Novartis advances MS innovation with remibrutinib data at MSToronto2026
Novartis presented late-breaking data on its remibrutinib treatment for multiple sclerosis, alongside broader portfolio updates at MSToronto2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.